Clinical Trials Browser

Multiple Myeloma × Injections, Subcutaneous × 90 days × Clear all

NCT06223516 2026-03-27

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma